Health Care & Life Sciences » Biotechnology | Heat Biologics Inc.

Heat Biologics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
-
341.60
1,519.90
5,793.80
Cost of Goods Sold (COGS) incl. D&A
1,397.20
66.90
116.00
-
-
-
Gross Income
1,397.20
66.90
116.00
-
-
-
SG&A Expense
5,167.50
12,120.00
20,906.00
13,336.90
14,504.40
23,020.90
EBIT
6,564.60
12,186.90
21,022.00
13,127.30
13,118.60
17,464.40
Unusual Expense
30.40
7.30
-
-
224.30
495.90
Non Operating Income/Expense
54.30
16.20
198.00
670.80
101.30
117.80
Interest Expense
79.10
73.40
364.00
549.40
-
-
Pretax Income
6,609.90
12,243.20
21,122.00
12,974.80
13,219.40
17,576.80
Income Tax
-
-
-
-
809.50
985.50
Consolidated Net Income
8,909.90
12,243.20
21,122.00
12,974.80
12,409.90
16,591.30
Net Income
8,711.30
11,788.80
20,295.00
12,574.00
11,841.70
15,733.90
Net Income After Extraordinaries
8,711.30
11,788.80
20,295.00
12,574.00
11,841.70
15,733.90
Net Income Available to Common
9,073.00
11,788.80
20,295.00
12,574.00
11,841.70
15,733.90
EPS (Basic)
24.20
18.30
25.30
7.10
3.08
0.90
Basic Shares Outstanding
374.70
645.50
801.60
1,758.60
3,845.30
17,485.50
EPS (Diluted)
24.21
18.26
25.32
7.15
3.08
0.90
Diluted Shares Outstanding
374.70
645.50
801.60
1,758.60
3,845.30
17,485.50
EBITDA
6,558.30
12,120.00
20,906.00
12,995.20
12,984.50
17,227.10
Non-Operating Interest Income
10.10
40.60
66.00
31.10
22.20
265.80
Minority Interest Expense
198.50
454.40
827.00
400.80
568.20
857.40
Other After Tax Income (Expense)
2,300.00
-
-
-
-
-
Preferred Dividends
361.70
-
-
-
-
-

About Heat Biologics

View Profile
Address
801 Capitola Drive
Durham North Carolina 27713
United States
Employees -
Website http://www.heatbio.com
Updated 07/08/2019
Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The firm's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the firm's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers.